Back to Search Start Over

Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations

Authors :
T. S. Panevin
E. G. Zotkin
E. A. Troshina
G. V. Lukina
Source :
Научно-практическая ревматология, Vol 61, Iss 5, Pp 545-553 (2023)
Publication Year :
2023
Publisher :
IMA PRESS LLC, 2023.

Abstract

Rituximab is a chimeric (mouse and human) monoclonal antibody against B-lymphocytes (CD20). This drug is widely used in rheumatology in the treatment of rheumatoid arthritis, Sjogren’s syndrome, some systemic connective tissue diseases and vasculitis, as well as in hematology in lymphoproliferative diseases. Administration of rituximab leads to depletion of B-lymphocytes through various mechanisms, including antibody-dependent and complementdependent cytotoxic effects, as well as the regulation of apoptosis. Considering the mechanism of autoimmune damage in Graves’ disease, an autoimmune thyroid disease accompanied by thyrotoxicosis and endocrine ophthalmopathy (an autoimmune lesion of the accessory apparatus of the eye), the use of rituximab may be effective in these diseases. The review considers the currently available results of studies on the use of various doses of rituximab in these diseases.

Details

Language :
Russian
ISSN :
19954484 and 19954492
Volume :
61
Issue :
5
Database :
Directory of Open Access Journals
Journal :
Научно-практическая ревматология
Publication Type :
Academic Journal
Accession number :
edsdoj.8ff66be35b1465cbb631b4ad2812b6b
Document Type :
article
Full Text :
https://doi.org/10.47360/1995-4484-2023-545-553